{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T19:52:22Z","timestamp":1771962742690,"version":"3.50.1"},"reference-count":40,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2020.0878","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T17:38:52Z","timestamp":1607535532000},"source":"Crossref","is-referenced-by-count":9,"title":["Gene Therapy for Monogenic Inherited Disorders: Opportunities and Challenges"],"prefix":"10.3238","author":[{"given":"Janbernd","family":"Kirschner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni","family":"Cathomen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"11437","published-online":{"date-parts":[[2020,12,21]]},"reference":[{"key":"10.3238\/arztebl.2020.0878_ref1","unstructured":"Paul Ehrlich Institut: Gentherapeutika. www.pei.de\/DE\/arzneimittel\/atmp\/gentherapeutika\/gentherapeutika-node.html (last accessed on 26 February 2020)."},{"key":"10.3238\/arztebl.2020.0878_ref2","doi-asserted-by":"crossref","unstructured":"Cornu TI, Mussolino C, Cathomen T: Refining strategies to translate genome editing to the clinic. Nat Med 2017; 23: 415\u201323","DOI":"10.1038\/nm.4313"},{"key":"10.3238\/arztebl.2020.0878_ref3","doi-asserted-by":"crossref","unstructured":"Mingozzi F, High KA: Immune responses to AAV in clinical trials. Curr Gene Ther 2007; 7: 316\u201324","DOI":"10.2174\/156652307782151425"},{"key":"10.3238\/arztebl.2020.0878_ref4","doi-asserted-by":"crossref","unstructured":"Miesbach W, Schw\u00e4ble J, M\u00fcller MM, Seifried E: Treatment options in hemophilia. Dtsch Arztebl Int 2019; 116: 791\u20138","DOI":"10.3238\/arztebl.2019.0791"},{"key":"10.3238\/arztebl.2020.0878_ref5","doi-asserted-by":"crossref","unstructured":"Pasi KJ, Rangarajan S, Mitchell N, et al.: Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N Engl J Med 2020; 382: 29\u201340","DOI":"10.1056\/NEJMoa1908490"},{"key":"10.3238\/arztebl.2020.0878_ref6","doi-asserted-by":"crossref","unstructured":"Perrin GQ, Herzog RW, Markusic DM: Update on clinical gene therapy for hemophilia. Blood 2019; 133: 407\u201314","DOI":"10.1182\/blood-2018-07-820720"},{"key":"10.3238\/arztebl.2020.0878_ref7","doi-asserted-by":"crossref","unstructured":"Maguire AM, Russell S, Wellman JA, et al.: Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials. Ophthalmology 2019; 126: 1273\u201385","DOI":"10.1016\/j.ophtha.2019.06.017"},{"key":"10.3238\/arztebl.2020.0878_ref8","doi-asserted-by":"crossref","unstructured":"Russell S, Bennett J, Wellman JA, et al.: Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 2017; 390: 849\u201360","DOI":"10.1016\/S0140-6736(17)31868-8"},{"key":"10.3238\/arztebl.2020.0878_ref9","doi-asserted-by":"crossref","unstructured":"Finkel RS, Mercuri E, Darras BT, et al.: Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017; 377: 1723\u201332","DOI":"10.1056\/NEJMoa1702752"},{"key":"10.3238\/arztebl.2020.0878_ref10","doi-asserted-by":"crossref","unstructured":"Mercuri E, Darras BT, Chiriboga CA, et al.: Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 2018; 378: 625\u201335","DOI":"10.1056\/NEJMoa1710504"},{"key":"10.3238\/arztebl.2020.0878_ref11","doi-asserted-by":"crossref","unstructured":"Mendell JR, Al-Zaidy S, Shell R, et al.: Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 2017; 377: 1713\u201322","DOI":"10.1056\/NEJMoa1706198"},{"key":"10.3238\/arztebl.2020.0878_ref12","unstructured":"Feldman AG, Parsons JA, Dutmer CM, et al.: Subacute liver failure following gene replacement therapy for spinal muscular atrophy Type I. J Pediatr 2020; S0022\u20133476(20)30682-X. Epub ahead of print."},{"key":"10.3238\/arztebl.2020.0878_ref13","doi-asserted-by":"crossref","unstructured":"Servais L, Kirschner J, Muntoni F: Randomisation versus prioritisation in a\u00a0managed access programme: lessons from spinal muscular atrophy. Neuromuscul Disord 2020; 30: 267\u20139","DOI":"10.1016\/j.nmd.2020.03.006"},{"key":"10.3238\/arztebl.2020.0878_ref14","unstructured":"Ziegler A, M\u00fcller-Felber W, Hahn A, von Moers A, Schara U, Kirschner J: Spinale Muskelatrophie: Gentherapie ohne Zulassung. Dtsch Arztebl 2019; 116: A-2232."},{"key":"10.3238\/arztebl.2020.0878_ref15","doi-asserted-by":"crossref","unstructured":"Kirschner J, Bernert G, v. der Hagen M, et al.: Zur Gentherapie der Spinalen Muskelatrophie mit Onasemnogene Abeparvovec. Stellungnahme der Gesellschaft f\u00fcr Neurop\u00e4diatrie. Monatsschr Kinderheilkd 2020; 168: 938\u201341","DOI":"10.1007\/s00112-020-00944-6"},{"key":"10.3238\/arztebl.2020.0878_ref16","unstructured":"Kirschner J, Butoianu N, Goemans N, et al.: European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur J Paediatr Neurol 2020; S1090\u20133798(20)30142\u20132."},{"key":"10.3238\/arztebl.2020.0878_ref17","doi-asserted-by":"crossref","unstructured":"Duan D: Systemic AAV micro-dystrophin gene therapy for duchenne muscular dystrophy. Mol Ther 2018; 26: 2337\u201356","DOI":"10.1016\/j.ymthe.2018.07.011"},{"key":"10.3238\/arztebl.2020.0878_ref18","doi-asserted-by":"crossref","unstructured":"Vandersmissen I, Biancalana V, Servais L, et al.: An integrated modelling methodology for estimating the prevalence of centronuclear myopathy. Neuromuscul Disord 2018; 28: 766\u201377","DOI":"10.1016\/j.nmd.2018.06.012"},{"key":"10.3238\/arztebl.2020.0878_ref19","unstructured":"Audentes: Audentes therapeutics tresents new positive data from ASPIRO, the clinical trial evaluating AT132 in patients with X-linked myotubular myopathy (XLMTM), at the 24th International Annual Congress of the World Muscle Society. www.audentestx.com\/press_release\/audentes-therapeutics-presents-new-positive-data-aspiro-clinical\/ (last accessed on 26 February 2020)."},{"key":"10.3238\/arztebl.2020.0878_ref20","doi-asserted-by":"crossref","unstructured":"Paulk N: Gene therapy: it\u2019s time to talk about high-dose AAV. www.genengnews.com\/topics\/genome-editing\/gene-therapy-its-time-to-talk-about-high-dose-aav\/ (last accessed on 20 July 2020)","DOI":"10.1089\/gen.40.09.04"},{"key":"10.3238\/arztebl.2020.0878_ref21","unstructured":"European Medicine Agency: Zusammenfassung der Merkmale des Arzneimittels Strimvelis www.ema.europa.eu\/en\/documents\/product-information\/strimvelis-epar-product-information_de.pdf (last accessed on 20 July 2020)."},{"key":"10.3238\/arztebl.2020.0878_ref22","doi-asserted-by":"crossref","unstructured":"Cavazzana M, Bushman FD, Miccio A, Andre-Schmutz I, Six E: Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges. Nat Rev Drug Discov 2019; 18: 447\u201362","DOI":"10.1038\/s41573-019-0020-9"},{"key":"10.3238\/arztebl.2020.0878_ref23","doi-asserted-by":"crossref","unstructured":"Booth C, Romano R, Roncarolo MG, Thrasher AJ: Gene therapy for primary immunodeficiency. Hum Mol Genet 2019; 28: R15\u2013R23","DOI":"10.1093\/hmg\/ddz170"},{"key":"10.3238\/arztebl.2020.0878_ref24","doi-asserted-by":"crossref","unstructured":"Schuessler-Lenz M, Enzmann H, Vamvakas S: Regulators\u2018 advice can make a difference: European Medicines Agency approval of zynteglo for beta thalassemia. Clin Pharmacol Ther 2020; 107: 492\u20134","DOI":"10.1002\/cpt.1639"},{"key":"10.3238\/arztebl.2020.0878_ref25","unstructured":"European Medicine Agency: Zusammenfassung der Merkmale des Arzneimittels Zynteglo. www.ema.europa.eu\/en\/documents\/product-information\/zynteglo-epar-product-information_de.pdf (last accessed on 20 July 2020)."},{"key":"10.3238\/arztebl.2020.0878_ref26","unstructured":"Universit\u00e4tsklinikum Regensburg: Positive Ergebnisse der Gentherapie CRISPR\/ Cas9 auch bei Patienten mit Sichelzellerkrankung. (last accessed on 1 November 2020)."},{"key":"10.3238\/arztebl.2020.0878_ref27","doi-asserted-by":"crossref","unstructured":"Naehrig S, Chao CM, Naehrlich L: Cystic fibrosis\u2014diagnosis and treatment. Dtsch Arztebl Int 2017; 114: 564\u201374","DOI":"10.3238\/arztebl.2017.0564"},{"key":"10.3238\/arztebl.2020.0878_ref28","unstructured":"Alton E, Armstrong DK, Ashby D, et al.: Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 2015; 3:\u00a0684\u201391"},{"key":"10.3238\/arztebl.2020.0878_ref29","doi-asserted-by":"crossref","unstructured":"Yan Z, McCray PB, Jr., Engelhardt JF: Advances in gene therapy for cystic fibrosis lung disease. Hum Mol Genet 2019; 28: R88\u2013R94","DOI":"10.1093\/hmg\/ddz139"},{"key":"10.3238\/arztebl.2020.0878_ref30","doi-asserted-by":"crossref","unstructured":"Schorling DC, Pechmann A, Kirschner J: Advances in treatment of spinal muscular atrophy\u2014new phenotypes, new challenges, new implications for care. J Neuromuscul Dis 2020; 7: 1\u201313","DOI":"10.3233\/JND-190424"},{"key":"10.3238\/arztebl.2020.0878_ref31","unstructured":"Novartis: Zolgensma\u00ae data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event- free survival, motor milestone achievement and durability now up to 5 years post-dosing www.avexis.com\/Content\/pdf\/newsarticle-IVasset-20200323.pdf (last accessed on 8 August 2020)."},{"key":"10.3238\/arztebl.2020.0878_ref32","doi-asserted-by":"crossref","unstructured":"Vill K, Kolbel H, Schwartz O, et al.: One year of newborn screening for SMA\u2014results of a german pilot project. J Neuromuscul Dis 2019; 6: 503\u201315","DOI":"10.3233\/JND-190428"},{"key":"10.3238\/arztebl.2020.0878_ref33","doi-asserted-by":"crossref","unstructured":"Pechmann A, Konig K, Bernert G, et al.: SMArtCARE\u2014a platform to collect real-life outcome data of patients with spinal muscular atrophy. Orphanet J Rare Dis 2019; 14: 18","DOI":"10.1186\/s13023-019-0998-4"},{"key":"10.3238\/arztebl.2020.0878_ref34","doi-asserted-by":"crossref","unstructured":"McGettigan P, Alonso Olmo C, Plueschke K, et al.: Patient registries: an underused resource for medicines evaluation: operational proposals for increasing the use of patient registries in regulatory assessments. Drug Saf 2019; 42: 1343\u201351","DOI":"10.1007\/s40264-019-00848-9"},{"key":"10.3238\/arztebl.2020.0878_ref35","doi-asserted-by":"crossref","unstructured":"Stausberg J, Maier B, Bestehorn K, et al.: Memorandum Register f\u00fcr die Versorgungsforschung: Update 2019. Gesundheitswesen 2020; 82: e39-e66","DOI":"10.1055\/a-1083-6417"},{"key":"10.3238\/arztebl.2020.0878_ref36","unstructured":"Gemeinsamer Bundesausschuss: G-BA konkretisiert Verfahren zu anwendungsbegleitender Datenerhebung \u2013 Gentherapie Zolgensma erster Fall. www.g-ba.de\/presse\/pressemitteilungen\/874\/ (last accessed on 20 July 2020)."},{"key":"10.3238\/arztebl.2020.0878_ref37","unstructured":"Korzilius H: Arzneimittel: Modelle f\u00fcr gerechtere Preise. Dtsch Arztebl 2019; 116: A-503"},{"key":"10.3238\/arztebl.2020.0878_ref38","unstructured":"European Medicine Agency: PRIME: priority medicines. www.ema.europa.eu\/en\/human-regulatory\/research-development\/prime-priority-medicines (last accessed on 26 February 2020)."},{"key":"10.3238\/arztebl.2020.0878_ref39","doi-asserted-by":"crossref","unstructured":"Buning H, Srivastava A: Capsid modifications for targeting and improving the efficacy of AAV vectors. Mol Ther Methods Clin Dev 2019; 12: 248\u201365","DOI":"10.1016\/j.omtm.2019.01.008"},{"key":"10.3238\/arztebl.2020.0878_ref40","unstructured":"World Health Organization: Nomenclature schemes for advanced therapies. www.who.int\/medicines\/services\/inn\/Nomenclature_schemes_advanced_therapies_201707.pdf (last accessed on 20 July 2020)."}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2020.0878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T10:38:42Z","timestamp":1638787122000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2020.0878"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,21]]},"references-count":40,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2020.0878","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,21]]}}}